Alumis Inc.
ALMS
Rangering i aksjer
#9827
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Aksjekurs
$6.78
Sist synkronisert: 2026-10-21
Markedsverdi
$877.57M
Endring (1 dag)
1.19%
Endring (1 år)
198.68%
Land
US
Handel Alumis Inc. (ALMS)
Kategori
Healthcare
Aksjeprishistorikk for Alumis Inc. (ALMS)
Høyeste sluttskurs: $2.34 den 2025-05-01
Laveste sluttskurs: $21.58 den 2023-05-01
Laveste sluttskurs: $21.58 den 2023-05-01
Aksjeprishistorikk for Alumis Inc. fra 2023 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2025 | -35.06% |
| 2024 | -49.49% |
| 2023 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
